Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BB

Ratings ESG MSCI

Ratings Zydus Lifesciences Limited: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: Zydus Lifesciences Limited
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: Zydus Lifesciences Limited
  • The company's enterprise value to sales, at 3.29 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Rating Financials

Zydus Lifesciences Limited SectorIndia

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Zydus Lifesciences Limited SectorIndia

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Zydus Lifesciences Limited SectorIndia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Zydus Lifesciences Limited SectorIndia

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Zydus Lifesciences Limited SectorIndia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
9.63B
BB
44.13B
BB
33.32B
BBB
30.13B
A
12.44B
A
8.4B
BB
-
7.81B -
6.79B - - - - - - -
6.72B
AA
6.22B
B
Average 16.56B
BBB
Weighted average by Cap.
BBB
See all sector ratings
  1. Stock Market
  2. Equities
  3. ZYDUSLIFE Stock
  4. Ratings Zydus Lifesciences Limited